Importance of molecular diagnostic of viral infections in renal transplant recipients by Rurenga-Gard, Lilli
  
 University of Groningen




IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Rurenga-Gard, L. (2019). Importance of molecular diagnostic of viral infections in renal transplant
recipients. [Groningen]: Rijksuniversiteit Groningen. https://doi.org/10.33612/diss.92267443
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
532839-L-sub01-bw-Gard
Processed on: 10-7-2019 PDF page: 83
CHAPTER 5
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It remains unclear whether overall degree of immunosuppression or specific effects of individual 
immunosuppressive agents are causal for increased occurrence of BK polyomavirus (BKPyV) 
infection in renal transplant recipients (RTR).
Methods
A prospective, multi-center, open-label randomized controlled trial in 361 de novo renal 
transplant recipients was performed. 224 RTR were randomised at 6 months into three 
treatment groups with duo therapy consisting of prednisolone and either cyclosporine A (CsA), 
mycophenolate sodium (MPS), or everolimus (EVL). Primary outcomes were incidence of BK 
viruria, BK viremia and BK nephropathy.
Results
From 6 months, incidence of BK viruria in de the MPS group (43.6%) was significantly higher 
than in the other groups (CsA: 16.9%, EVL: 19.8%) (p=0.003). BKPyV nephropathy was diagnosed 
in 3 patients, all treated with MPS (7.8%, p = 0.001). Longitudinal data analysis showed a lower 
BKPyV load and a significantly faster clearance of BK viruria in the CsA group compared to the 
MPS group (p = 0.03).
Conclusions
Treatment with MPS was associated with and increased incidence of BK viruria. Duo-
immunosuppressive therapy with cyclosporine A and prednisolone was associated with the 
lowest rate of BKPyV replication and the fastest clearance of the virus.
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INTRODUCTION
Changes in immunosuppressive protocols applied in transplantation medicine have led to 
decreased allograft rejection rates. Currently triple immunosuppressive regimens are mostly 
applied, including prednisolone, a calcineurin inhibitor (tacrolimus, cyclosporine A), and an 
antimetabolite (mycophenolic acid, mycophenolate mofetil). These drugs act on different 
phases of the immune proliferative steps, thereby inhibiting the immune response in a multi-
hit model.
With these new, more potent therapeutic strategies, other problems have emerged in the 
field of transplantation, such as viral infections with BK polyomavirus (BKPyV). BKPyV can 
cause hemorrhagic cystitis in patients after bone marrow transplantation and polyomavirus 
nephropathy (BKVAN) in renal transplantation recipients [1,2]. In the last decades an increase 
in BKPyV associated nephropathy up to 10% of renal transplant recipients (RTR) has been 
observed, with an associated risk to lose the allograft of up to 50% [2]. Multiple risk factors 
have been identified, including: HLA mismatching, donor age, deceased donor status, male 
gender, viral co-infections, and anti-rejection treatment with ATG or IVIG [3-6]. Currently, 
no effective anti-viral therapy is available for treatment of BKPyV replication. Reduction of 
immunosuppression e.g. reduction of MMF and/or calcineurin inhibitor is commonly regarded 
as the best method to control BKPyV replication, but increases the risk of allograft rejection 
[7-10].
Since immunosuppressants are regarded as important risk factors in the development of BK 
related pathology, the question remains if either one immunosuppressive agent or the total 
immunosuppressive load is responsible for this increased risk of developing BKVAN.
The aim of this study was to investigate the isolated effect of the calcineurin inhibitor 
cyclosporine A, the antimetabolite mycophenolate mofetil and M-TOR inhibitor everolimus 
on BKPyV replication and the duration of BK replication, and to study the clinical applicability 
of one of these agents as duo-immunosuppressive therapy, as a possible alternative for high 
risk transplant patients (patients with a high HLA mismatch, older patients, transplantations 
with a high cold ischemia time). In this study the incidence of BK viruria, viremia and BKVAN 
was studied in a randomized controlled, prospective multicentre trial with 224 de novo renal 
transplant recipients receiving duo immunosuppressive therapy consisting of prednisolone 
and either cyclosporine A, mycophenolate sodium, or everolimus.
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From November 2005 till June 2009 a total of 361 renal transplant recipients (RTR) between 
18 and 70 years, receiving a first or second renal transplant at the University Medical Center 
Groningen (UMCG), Academic Medical Center of Amsterdam (AMC) or Leiden University Medical 
Center (LUMC), were enrolled in a prospective, multi-center, open-label randomized controlled 
trial. Exclusion criteria were: HLA-identical sibling donor, a third or fourth transplant, current or 
historical panel reactive antibodies of more than 50%, ABO-incompatibility, a serum cholesterol 
> 8.5 mmol/l despite adequate HMG co-A reductase inhibition and female patients unwilling 
to use adequate contraception.
During the first 6 months post transplantation patients were treated with a similar standard 
immunosuppressive regimen. Details about this study protocol are described by Bemelman et 
al. [11]. Briefly, induction therapy consisted of 20 mg basiliximab (Simulect®, Novartis Pharma) 
intravenously prior to transplantation and on day 4 post transplantation, prednisolone 50 mg 
once daily from day 1-4, followed by 10 mg once daily from day 4 onwards, mycophenolate-
sodium (Myfortic®, Novartis Pharma) 720 mg/day from day 1 onwards, and cyclosporine-micro-
emulsion (CsA, Neoral®, Novartis Pharma) from day 1 onwards. Dosage of CsA was calculated 
with estimated drug exposure, using population-based pharmacokinetic modelling, with 
serial (full and limited) sampling for calculation of the areas-under-the-concentration-over-
time curves (AUC12). Target values of AUC12 for CsA were 5400 mcg*h/L in the first six weeks 
and 3250 mcg*h/L thereafter [11].
Follow-up of the study was 24 months after renal transplantation. Patients underwent 
a renal biopsy at 6 months, and at 24 months. Biopsy-proven rejection was treated with 
methylprednisolone pulses. Refractory rejection episodes were treated with rabbit 
antithymocyte globulin (5 doses 2.5 mg/kg rATG: Merieux) [11].
Renal transplant recipients (RTR) with no sign of rejection in the protocol biopsy at 6 months 
after transplantation were randomized into three different treatment arms, consisting of 
prednisolone and cyclosporine A (target AUC12 3250 mcg*h/L) (CsA); prednisolone and MPS 
(target AUC12 40 mg*h/L or a trough level > 2 mg/mL) (MPS); or prednisolone and everolimus 
(target AUC12 150 mg*h/L) (EVL). Patients with signs of (sub)clinical rejection in the 6 month 
protocol biopsy were excluded from the study and received triple immunosuppressive therapy 
consisting of prednisolone, cyclosporine A and mycophenolate sodium. Prednisolone dose was 
5-10 mg daily. After enrolling 39 RTR, inclusion of patients in the MPS arm was prematurely 
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stopped by the Data Safety Monitoring Board due to an unacceptable high rate of acute 
rejection. In patients with clinical rejection, CsA was added to the immunosuppressive protocol.
During the total study period urine and serum samples were collected at baseline, 2 weeks, 
6 weeks, 3, 6, 12, 18 and 24 months and stored at -20°C. Baseline was defined as the day of 
transplantation, shortly before transplantation. BK viral load was measured retrospectively. 
Protocol biopsies and biopsies performed under suspicion of BK nephropathy, were stained 
for simian virus 40 (SV40) large T antigen. Histological proven BK nephropathy was defined 
as interstitial inflammation and tubulitis in combination with a positive SV40 nuclear staining 
in tubular epithelial cells. In this clinical trial therapy adaptations upon BK infection were not 
protocolized. Renal transplant recipients with signs of (subclinical) rejection in the 6 months 
protocol biopsy were excluded from the immunosuppressive study protocol, but were 
monitored with the same monitoring intervals as RTR who were included, including serum 
and urine sampling and a renal biopsy at t = 24 months at the time points mentioned above. 
Results from 0-6 months and 6-24 months were analysed separately. Patients ID and project 
number retrospectively provided comparison of the three research groups in data from 0-6 
in patients that were to be randomized at t = 6 months, which enabled base line comparison.
The study was conducted according to the Good Clinical Practice guidelines and in accordance 
to the ethical principles of the Declaration of Helsinki and was approved by the Dutch Medical 
Ethical Board for medical research. All patients gave written informed consent. The study was 
registered under the Dutch Medical Ethical Committee Trial ID: NTR1615, Acronym: MECANO).
BKPyV real time polymerase chain reaction (RT PCR)
An internally controlled in-house developed quantitative BKPyV RT-PCR, amplifying a 131bp of 
the VP2 gene, with a detection limit of 2 log 10 copies/ml, was used for the detection of BKPyV 
DNA (Supplementary table 1). BK viruria and BK viremia were defined as a concentration of 
BKPyV > 2 log 10 copies/ml in urine and serum respectively. The term ‘return to latency’ was 
defined as a concentration < 2 log 10 copies/ml BKPyV in urine subsequent to a positive urine 
test.
According to the manufacturer’s instructions, DNA was extracted from 190µl sample with the 
addition of 10µl internal control, Phocine herpesvirus (PhHV) [12]. PCR reactions were performed 
in a total reaction volume of 50µl, consisting of 20µl DNA, 2x Taqman Universal Mastermix 
(Life Technologies, USA), 300nM of primers, 100nM of probes, 5mg/ml Bovine serum albumin 
and DNAse/RNAse free water (Sigma). The PCR reactions were run on the ABI PRISM7500 (Life 
Technologies, USA), with thermal profile: 50°C for 2min, 95°C for 10min followed by 42 cycles 
of 95°C for 15sec, 60°C for 1 min.
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Statistical analysis was performed using IBM SPSS Statistics 22. Baseline characteristics and 
incidence of BK infection (viruria, viremia, nephropathy) between the three different treatment 
groups, primary infections and reactivations were compared using Chi-square test and ANOVA 
for categorical variables and continuous variables, respectively. Statistical analyses were 
performed based on intention to treat population (ITT). Longitudinal data were analysed using 
generalised estimating equations (GEE) with an exchangeable correlation matrix. Short term 
effect (0-6 months) and long term effect (6-24 months) were analysed separately. Estimated 
marginal means (EMM) with 95% confidence intervals from the GEE analyses were plotted in 
graphs. Biopsy proven acute rejection during 24 months was compared using survival analysis 




In this study 361 RTR were enrolled of whom 276 RTR underwent a protocol biopsy at 6 months. 
Reasons for discontinuation of the study are listed in Figure 1. Borderline changes, Banff grade-
1A, grade 1B or higher acute rejection were found in 50 of 276 RTR, and two RTR were excluded 
due to other complications. In total 224 RTR were randomized into the three different treatment 
groups. In patients not randomized at 6 months the number of deceased donors and the 
cold ischemia time were significantly higher, compared to patients randomized at 6 months 
(Supplementary table 2). In the patients randomized at 6 months baseline characteristics 
between the three different treatment groups did not differ significantly (Table 1).
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Male N (%) 56 (62.9) 25 (64.1) 62 (64.6) 0.97
Age, years ± S.D. 49.2 ± 12.8 53.2 ± 11.2 51.0 ± 12.8 0.23
Caucasian n (%) 81 (91,0) 32 (82,1) 81 (84,4) 0.27
Primary disease leading to end 
stage renal failure, n (%)
0.99
Polycystic kidney disease 21 (23.6) 9 (23.1) 20 (20.8)
Glomerulonephritis 17 (19.1) 5 (12.8) 17 (17.7)
Diabetes Mellitus 2 (2.2) 2 (5.1) 4 (4.2)
Pyelonephritis or interstitial nephritis 3 (3.4) 0 (0) 3 (3.1)
Focal segmental glomerulosclerosis 3 (3.4) 2 (5.1) 4 (4.2)
Urologic 5 (5.6) 2 (5.1) 10 (10.4)
Hypertension 13 (14.6) 9 (23.1) 15 (15.6)
Vascular 4 (4.5) 2 (5.1) 5 (5.2)
Other 21 (23.6) 8 (20.5) 18 (18.8)
Total HLA mismatch, mean ± S.D. 2.81 ± 1.54 2.81 ± 1.80 2.86 ± 1.50 0.96
Number of kidney transplantation 
absolute numbers n (%)
0.75
1 85 (95.5) 36 (92.3) 90 (93.8)
2 4 (4.5) 3 (7.7) 6 (6.2)
Donor characteristics
Age, years ± S.D. 44.3 ± 19.4 37.7 ± 21.0 46.1 ± 17.4 0.06
Type of transplantation (%) 0.41
Living related 23 (25.8) 6 (15.4) 21 (21.9)
Living unrelated 30 (33.7) 10 (25.6) 29 (30.5)
Deceased donor heart beating 23 (25.8) 16 (41) 28 (29.5)
Donation after cardiac death 13 (14.6) 7 (17.9) 17 (17.9)
Cold ischemia time, deceased donors 
only, hours ± S.D.
16.7 ± 5.7 16.1 ± 5.6 14.9 ± 6.2 0.37
a: CsA: prednisolone + cyclosporine A, b: MPS: prednisolone + mycophenolate sodium, c: EVL: prednisolone + everolimus
In all three research groups together, from 6-24 months, 558 of 896 time points samples were 
collected and available for analysis (62.3%). In total 157 of the 224 randomized RTR (70%) were 
treated per protocol, completed follow-up and underwent a renal biopsy at 24 months (Figure 
1). Of the 89 RTR assigned to treatment with CsA, 74 (83%) were still treated according to 
protocol two years after transplantation, versus 58 of 96 (60%) RTR in the EVL group, and 25 of 
39 (64%) RTR in the MPS group. Figure 1 summarizes randomization of patients and reasons 
for discontinuation of the study protocol.
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Figure 1: Patient disposition of eligible de novo renal transplant recipients. 
ITT population: all patients randomized after the 6 month biopsy; PP population: all patients who completed study without 
major protocol deviations; Safety population: all patients who received at least one dose of study drug and had at least one 
post-baseline safety assessment; CsA: prednisolone + cyclosporine A, MPS: prednisolone + mycophenolate sodium, EVL: 
prednisolone + everolimus, CNI: calcineurin inhibitor.
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Drug exposure
From 0 to 6 months, no differences in mean CsA and MPS AUC12hrs in the three treatment groups, 
randomized at 6 months, were found. No differences in mean CsA and MPS AUC12hrs were found 
between randomized and not randomized patients at 6 months. In the CsA group CsA AUC12hrs 
at 6 and 24 months were 3280 ± 971 mcg*h/L and 3278 ± 907 mcg*h/L, respectively. Mean 
AUC12hrs in the MPS group were 47 ± 20 mg*h/L at 6 months and 49 ± 23 mg*h/L at 24 months. 
In the EVL group the mean AUC12hrs was 203 ± 21 mg*h/L one month following conversion and 
159 ± 44 mg*h/L at 24 months. Mean AUC12hrs of the CsA, MPS and EVL group at 6, 7, 12, 18 and 
24 months are depicted in Supplementary figure 1. Prednisolone exposure was not measured 
via area under the curve. Prednisolone doses at t = 6, 7, 12, 18 and 24 are depicted for the three 
treatment groups in Supplementary figure 2 and did not differ between the three groups.
Primary outcomes BK viruria, viremia, and BKVAN
BK viruria
Of the 224 patients included, 65 tested positive for BKPyV replication (29.0%). From 0 to 6 
months, no differences in BKPyV replication are seen between the three treatment groups. 
In this period the incidence of BKPyV replication in urine was 12 (13.5%) in the CsA group, 8 
(20.5%) in the MPS group and 16 (16.7%) in the EVL group (p = 0.60). From 6 to 24 months the 
incidence of BK viruria was 15 (16.9%) in the CsA, 17 (43.6%) in the MPS and 19 (19.8%) in the 
EVL group (p = 0.003). The incidence of viruria, between patients randomized at 6 months and 
patients who were not randomized, was not significantly different (Supplementary table 3). 
Furthermore, the incidence of viruria between patients treated per protocol and patients who 
switched from immunosuppression due to medical reasons, did not differ significantly in the 
three treatment groups (Supplementary table 4).
BK viremia and BKVAN
In total 31 RTR tested positive for BKPyV replication in serum. Incidence of BK viremia before 
6 months was 7 (7.9%), 3 (7.7%) and 6 (6.3%) in the CsA, MPS and EVL group, respectively 
(p = 0.90). From 6 to 24 months the incidence of BK viremia in the three groups was 4 (4.5%), 
3 (7.7%) and 3 (3.1%) (p = 0.51). Three patients developed BK nephropathy. All three patients 
were treated with MPS (p = 0.001) (1.3% of the total cohort, 7.7% of MPS). In Table 2 primary 
outcome of the study from 6 to 24 months are depicted. The incidence of BK viremia and BKVAN 
within 24 months was not significantly different between randomized patients (n = 224) versus 
patients excluded at 6 months (n = 137) (Supplementary table 3) and incidence of BK viremia 
and BKVAN did not differ between patient treated per protocol and patients who switched 
from immunosuppression during the study (Supplementary table 4).
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BK viruria N (%) 15 (16.9) 17 (43.6) 19 (19.8) 51 (22.8) 0.003
BK viremia N (%) 4 (4.5) 3 (7.7) 3 (3.1) 10 (4.5) 0.51
BK nephropathy (%) 0 (0.0) 3 (7.7) 0 (0.0) 3 (1.3) 0.001
a: CsA: prednisolone + cyclosporine A, b: MPS: prednisolone + mycophenolate sodium, c: EVL: prednisolone + everolimus.
Longitudinal analysis
GEE analysis of long term effect (t = 6 - 24 months) was performed on the BKPyV viral load in 
urine (Figure 2). Longitudinal estimated marginal means (EMM) of concentration of BKPyV (log 
10 copies/ml) in urine from 6 to 24 months are depicted in Figure 2A. A significantly lower mean 
BKPyV concentration, from 6 to 24 months, was found in the CsA group compared to the MPS 
(p = 0.002) and the EVL group (p = 0.004) with an EMM of 1.27, 2.55 and 2.46 log10 copies/ml 
in the CsA, MPS and EVL group respectively. This difference remained statistically significant 
after adjustment for donor age, donor type, CMV status of the donor, and HLA mismatch (A, B 
and DR) (CsA versus MPS p = 0.004, CsA versus EVL p = 0.03) (Figure 2A).
In Figure 2B the course of BKPyV viral loads EMM in urine over 24 months is displayed. BKPyV 
viral load in urine decreased in the CsA group with an EMM from 6 to 24 months of 2.07 to 0.63 
log 10 copies/ml, whereas it remained persistently high in the MPS group with an EMM from 
6 to 24 months of 2.20 to 2.43 log 10 copies/ml (p = 0.05) (Figure 2B). This difference became 
significant after adjustment for donor type, donor age, CMV status donor, HLA mismatch (A,B 
and DR), with an EMM in the CsA group from 6 - 24 months of 2.26 of 0.86 log 10 copies/ml, and 
an EMM in the MPS group of 2.46 to 2.66 log 10 copies/ml (p = 0.03).
In serum no significant differences in course of BKPyV infection were found.
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Figure 2: Longitudinal analysis of BK viruria. 
Estimated marginal means (EMM) of BKPyV load (log
10
 copies/ml) from t = 6 months to t = 24 months by treatment group, 
prednisolone + cyclosporine A (black), prednisolone + MPS (checkered), prednisolone + everolimus (white) (Figure 2A). 
Longitudinal course of BKPyV infection in the three treatment groups, prednisolone + cyclosporine A (black circles), prednisolone 
+ MPS (open squares) and prednisolone + everolimus (black crosses) (Figure 2B). P values were calculated using GEE with an 
exchangeable correlation structure.
Death, graft loss and biopsy proven acute rejection (BPAR)
The combined incidence of death, graft loss and allograft rejection from 6 to 24 months was 13 
(14.6%), 9 (23.1%) and 5 (5.2%) in the CsA, MPS and EVL group, respectively (p = 0.001). In total 
8 (9.0%), 8 (20.5%) and 1 (1.0%) biopsy proven acute rejection (BPAR) episodes were reported 
in the CsA, MPS and EVL group between 6 months and 24 months (Figure 3, p < 0.001). These 
were clinical rejections in ‘for cause’ biopsies - biopsies on indication - in 100% of the cases. No 
signs of clinical rejection were found in the 24 months protocol biopsies. The majority of these 
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Figure 3: Kaplan-Meier estimate of time to biopsy proven acute rejection (BPAR) over 24 months of 
treatment. 
Percentages of patients without allograft rejection are plotted against time in the three treatment groups (A). Black line: 
prednisolone + cyclosporine A, long dashed line: prednisolone + MPS, short dashed line: prednisolone + everolimus. Patients 
with and without BKPyV infection in the prednisolone + MPS group were plotted (B). Log-rank test was used to determine P 
values.










Primary composite endpoint (%) 13 (14.6) 9 (23.1) 5 (5.2) 27 (12.1) 0.001
Death 1 (1.1) 0 (0.0) 4 (4.2) 5 (2.2)
Graft loss 3 (3.4) 1 (2.6) 0 (0.0) 4 (1.8)
Number of BPAR total 8 (9.0) 8 (20.5) 1 (1.0) 17 (7.6)
Biopsy proven acute rejection 
(BPAR) by Banff grade (%)
0.002
I 7 (7.9) 8 (20.5) 1 (1.0) 16 (7.1)
II 1 (1.1) 0 (0.0) 0 (0.0) 1 (0.4)
III 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
a: CsA: prednisolone + cyclosporine A, b: MPS: prednisolone + mycophenolate sodium, c: EVL: prednisolone + everolimus, 
BPAR: biopsy proven acute rejection.
When the sequence of rejection and BKPyV related pathology is examined, most BKPyV 
infection episodes are not related with episode of allograft rejection. No significant differences 
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in incidence of BK viruria or viremia, after an episode of allograft rejection, were found between 
the three treatment groups (Supplementary table 5 and 6). BKVAN was exclusively found in 
the MPS group. These three cases of BKVAN were in patients who did not experience allograft 
rejection during their 24 months post transplantation follow up.
Renal function
Estimated glomerular filtration rates (eGFR, MDRD formula) were compared between BK 
viruria positive and BK viruria negative patients. At 24 months mean eGFR was 38.8 and 39.3 
mL/min/1.73 m2 in the BKPyV negative and BKPyV positive group and were not significantly 
different (p = 0.88) .
DISCUSSION
In this study, maintenance treatment with duo immunosuppressive therapy with prednisolone 
and mycophenolate sodium was associated with an increased risk of BK viruria. In contrast, 
patients treated with prednisolone and either cyclosporine A or everolimus had a low 
incidence of BK viruria. Furthermore, while 3 cases of BKVAN occurred in the prednisolone and 
mycophenolate sodium group, no BKVAN was observed in patients treated with prednisolone 
in combination with either cyclosporine A or everolimus within 24 months post-transplantation. 
Longitudinal analysis showed a significantly better clearance of BK viruria in patients treated 
with cyclosporine A, with undetectable viral loads (< 2 log 10 copies/ml) from 12 months onwards, 
while patients treated with mycophenolate sodium or everolimus maintained higher levels of 
BK viruria up to 24 months. We therefore draw three main conclusions. First, in this study with 
relative low immunosuppression, the incidence of BKVAN and BKPyV related pathology was 
considerably lower than the incidence described in the literature. Second, BKPyV associated 
nephropathy only occurred in patients treated with prednisolone and mycophenolate sodium. 
Third, immunosuppressive therapy with prednisolone and cyclosporine A was associated with 
a shorter return to latency period in case of BKPyV infection, than either prednisolone and MPS, 
or prednisolone and everolimus.
Many studies have described BKPyV infection and BKPyV related pathology in RTR patients 
treated with triple immunosuppressive therapy. Some studies found an increased risk of BKVAN 
using tacrolimus compared to cyclosporine A [13-15]. Furthermore, there are several studies 
that indicate a reduced risk of development of BKPyV related pathology in RTR treated with 
EVL and, either low dose CsA, or low dose tacrolimus, compared to MPA with CsA, or MPA with 
tacrolimus [6,16-18]. In contrast, our study is the first randomized clinical trial comparing long 
term prednisolone based duo immunosuppressive therapy following six months of uniform 
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triple therapy in RTR on incidence of BKPyV, thereby enabling the study of the isolated effect 
of different immunosuppressive agents on BKPyV replication.
Possible reasons for the effective clearance of BKPyV in patients treated with cyclosporine A 
can be found in in vitro studies. Several studies indicate a suppressive effect of cyclosporine 
A on BKPyV infected Vero E6 cells, which are renal tubular epithelial cells isolated from the 
African green monkey [19-22]. This could be an explanation for the low incidence of BK related 
pathology and effective clearance of the virus in patients treated with cyclosporine A.
Although we do not see an significant increase in the incidence of BK viremia in patients treated 
with MPS compared to CsA and EVL, we did observed an increased incidence of viruria and 
BKVAN. We therefore hypothesized that BKPyV infection is more severe, with prolonged 
infection episodes and can easier progress to BKVAN in this group, which was confirmed by 
our longitudinal analyses.
It is unclear whether MPS directly affects viral replication of BKPyV. But it is thought that MPS 
is important factor in maintaining and loss of BKPyV specific T cell immunity. Tapering of 
antimetabolite is generally accepted as the most effective treatment of BKPyV infection and 
this can restore BKPyV specific T cell constitution to levels enabling clearance of the virus [23-
26]. Loss of effective BKPyV specific immunity could be a reason for the increased incidence 
and prolonged detection of BKPyV in urine and increased occurrence of BKVAN in MPS treated 
patients in this study, thereby adding an additional reason to focus on tapering antimetabolite 
immunosuppressive drugs when encountering BKPyV replication and related pathology. 
Egli et al. reviewed the role of BKPyV specific T-cells and BKPyV specific immunity in BKPyV 
infection. They described that an increase of BKPyV specific T-cells measured directly ex vivo 
was only observed in patients with decreasing BKPyV plasma concentrations. Therefore, BKPyV 
specific immunity plays a pivotal role in BKPyV replication and progression to BKVAN versus 
viral clearance, and thereby this indicates a role for BKPyV specific T-cells as potential marker 
for regaining control over BKPyV replication[27].
Egli et al also concluded that risk stratification prior to transplantation can be achieved, but 
requires expansion of BKPyV specific T-cells in vitro combined with sensitive assays such as 
EliSpot or intracellular cytokine staining. Recent studies showed a 10 to 100 fold increase of 
BKPyV specific T-cells after in vitro stimulation in patients with BKVAN, indicating that BKPyV 
specific T-cells were present in these patients, but might be paralysed by immunosuppression 
and unable to control BKPyV replication until in vitro wash out and re-stimulation[27]. This 
strongly indicated an important role for immunosuppresants in suppressing BKPyV specific 
immunity and creates new opportunities for future applications of cellular immunotherapy [27].
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In the current study it is noticeable that the increased BKPyV loads in the EVL group are 
detectable up to 24 months, and this contradicts observations associating everolimus with 
reduced BKPyV replication, compared to other immunosuppressants [28-30]. Data of the 
pleiotropic effect of everolimus and the involved mechanisms are scarce and show multiple 
modes of action. Everolimus is involved in suppressing the cellular immune response via 
suppression of the Th1-response. This is established via inhibition of IL-2 signaling [31]. 
Moreover, reduced expression of viral surface antigens has been observed in hepatitis B positive 
patients treated with everolimus in the context of hepatocellular carcinoma [32]. In addition, 
in vitro data show a viral proliferative effect of everolimus in hepatitis E infection through 
inhibition of the PI3K-PKB-mTOR pathway, a new pathway that is involved in a gate keeping 
antiviral defense mechanism [33]. In contrast, Hirsch et al. found an inhibiting effect of the 
mTOR inhibitor sirolimus on BKPyV replication in renal epithelial cells [34]. Since everolimus is 
the 40-O-(2-hydroxyethyl) derivative of sirolimus one would expect similar properties of these 
agents. However, although both registered as mTOR inhibitor and both used is transplantation 
medicine, the two drugs can exert different effects on patients, such as different tissue and 
subcellular distribution, different affinities to active drug transporters and drug-metabolizing 
enzymes as well as differences in drug-target protein interactions[35] These effect are seen both 
in vitro and clinically in transplant recipients[35]. Futhermore, sirolimus related inhibition of 
BKPyV was principally seen in early infection (the first 24 hours post infection), whether in late 
infection, with late viral gene expression this effect was not observed, potentially restricting 
this effect of sirolimus on BKPyV replication to the early infection phase and supporting to the 
rationale that this early phase is an mTOR dependent process[34]. Translating these data to our 
study is highly speculative, but one of the above mentioned mechanisms could be involved in 
the protracted high BKPyV loads in urine measured in the EVL group. Furthermore treatment 
with duo immunosuppressive therapy could elicit these viral promoting effects, whereas these 
effects are obscured by effects of other immunosuppressants in treatment with triple drug 
therapy. However, whether these above mentioned mechanisms are also operative in BKPyV 
infection remains unclear and since we find opposing effects of some agents, further in vitro 
and in vivo research is needed.
As mentioned, this prospective multi-center, open-label randomized controlled trial offered 
the opportunity to study the isolated effects of cyclosporine A, MPS and everolimus on 
BKPyV replication. However, the study has some limitations. First, due to the clinical status, 
patients with a rejection episode before 6 months were excluded from the study. This group 
potentially consists of patients who were at increased risk of BKPyV infection, due to the 
necessity of increased immunosuppression. Still, excluded patients did not have increased 
frequencies of BKPyV related pathology compared to randomized patients. Second, in the 
current study, patients were not treated with tacrolimus, which is more frequently used in 
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current immunosuppressive regimens. In multiple studies, the combination of prednisolone, 
MPS and tacrolimus has been associated with a higher risk of BKPyV complications [15,18,36,37]. 
In this study we cannot directly compare the effect of cyclosporine A and tacrolimus on BKPyV 
replication. Third, the AUC measuring of drug exposure is a method that nowadays is less 
commonly used in the clinic. Unfortunately we cannot provide through levels of the drugs. 
Still the reported AUC data give an indication about the actual level of immunosuppression 
patients received in the three research groups. Lastly, BKPyV monitoring in urine and serum, 
and possible therapy adaptations upon BKPyV replication were not protocolized. However, this 
also minimized interventions and enables the study of long term viral load and viral clearance.
A possible confounding effect of the antirejection therapy in the MPS group, causing the BKPyV 
related pathology can be ruled out, since the post rejection incidence of BKPyV infection is 
very low and the incidence of this type of BKPyV infection did not differ between the three 
treatment groups. Furthermore methylprednisolone as antirejection therapy is not regarded 
as a risk factor for BKPyV infection or BKVAN as is demonstrated in several studies and 
reviews, while maintenance steroid therapy is [37-39]. However, drug doses of prednisolone 
are not higher in the MPS group than in the other treatment groups. A possible confounding 
effect of maintenance steroid therapy in the development of BKPyV infection and BKVAN 
is thereby unlikely. Lastly, a possible confounding effect of the switch of patients to other 
immunosuppressive medication during this study is also unlikely. Rates of BK viruria, viremia 
and BKVAN were compared between the patients treated per protocol and the patients who at 
some point switched of immunosuppression, which showed no significant differences between 
these subgroups (Supplementary table 4)
In summary, we can conclude from this study that duo-immunosuppressive therapy with 
mycophenolate sodium and prednisolone is associated with a prolonged BKPyV infection 
period and with a higher incidence of BKVAN, while treatment with cyclosporine A and 
prednisolone can be regarded as an effective treatment to limit BKPyV replication in the first 
two years post-transplantation. This can be done in an immunological low risk transplantation 
cohort, without increasing the risk of graft loss, or allograft rejection.
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